Document:

Exhibit 4.17

 

REVISED
CO-MARKETING AGREEMENT

 

This Revised
Co-Marketing Agreement (the “Agreement”) dated October 11, 2012, and which has come into effect on
1 September, 2012 (the “Effective Date”) is by and between Rosetta
Genomics Ltd., and its subsidiary, Rosetta Genomics Inc.,
a Delaware corporation, with offices at 3711 Market St., Suite 740, Philadelphia, PA 19104, USA (collectively, the “Company”)
and Precision Therapeutics, Inc., a Delaware corporation with offices
at 2516 Jane Street, Pittsburgh, PA 15203, USA (“Precision”).

 

Recitals

 

Whereas,
Company develops and provides certain diagnostic services; and

 

Whereas,
the Parties desire for Precision to act as the exclusive authorized representative, aside from the Company, to market and promote
certain Company products to customers in the United States, pursuant to the terms of this Agreement; and

 

Whereas,
Company and Precision previously entered into a co-marketing agreement effective July 23, 2012, the terms of which the parties
now wish to replace, in their entirety, with the terms in this Agreement;

 

Now
Therefore, in consideration of the mutual promises contained herein, the parties hereby agree as follows:

 

1.Definitions

 

1.1“Competing
Product” means any third-party product, service or laboratory developed test (“LDT”) with functionality that
is substantially similar to that of any Product covered under the terms of this Agreement and is marketed in such a manner and
in the Territory as to actually compete with such Product. For avoidance of doubt, this includes tests for [***]. By way of example
only, [***] test shall be considered a “Competing Product” hereunder.

 

1.2“Confidential
Information” means any confidential or proprietary information of a Party that is disclosed to the other Party under
this Agreement, which may include, without limitation, specifications, know-how, trade secrets, technical information, drawings,
models, business information, inventions, discoveries, methods, procedures, formulae, protocols, techniques, data, and unpublished
patent applications, whether disclosed in oral, written, graphic, or electronic form. All Information disclosed by either Party
pursuant to the Reciprocal Nondisclosure Agreement between the Parties dated November 2, 2011, as may be amended, shall be deemed
to be such Party’s Confidential Information disclosed hereunder.

 

1.3“Customer”
means a potential customer in the Territory for a Product, who is not a Joint Customer.

 

    	1

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

1.4“Joint
Customer” means [***].

 

1.5“Marks”
means Company’s trademarks, logos, and trade names placed on the Products or otherwise used in Company’s business and
made available to Precision in Company’s sole discretion and attached hereto as Exhibit
C.

 

1.6“Order”
means a binding, written purchase order for Products (typically made in the form of a test requisition form) placed by a Customer
or Joint Customer with Precision, as agent for the Company, or with Company, that results directly from the sales and marketing
activities performed by Precision under this Agreement. For avoidance of doubt, all other orders for Products, whether generated
by the Company or otherwise, shall not be considered “Orders.”.

 

1.7“Products”
means the Company products, services or laboratory developed tests listed in Exhibit A, as such list may be amended from time to
time by Company upon written notice to Precision.

 

1.8“Territory”
means the United States and its territories and possessions, including Puerto Rico.

  

2.Appointment
and Marketing

 

2.1Co-Exclusive
Appointment. Subject to the terms and conditions of this Agreement, Company hereby appoints Precision, and Precision hereby
accepts such appointment, as Company’s exclusive third party sales representative to promote and solicit Orders for Products
from Customers and Joint Customers within the Territory, aside from Company. For the removal of doubt, Company [***], during the
Term, as well as personnel employed directly by the Company, for the purpose of marketing Products, and this shall not constitute
a breach of the Agreement; provided that Company shall give Precision prior notice of [***].

 

2.2Marketing
Obligations. During the term of this Agreement, Precision will: (i) use commercially reasonable efforts to market and promote
the sale of the Products to Customers throughout the Territory in a legal, ethical, professional, and businesslike manner. Company
will have the right, but not the obligation, to review and incorporate suggestions for improvement of marketing collateral made
by Precision. Except as provided in this Section 2.2, Precision’s exercise of its rights to distribute Products will be entirely
at Precision’s option, and Precision is not obligated to distribute Products or to distribute any minimum quantity of Products.
Except as expressly provided in this Agreement, Precision will (i) bear all costs and expenses incurred in connection with Precision's
activities hereunder; (ii) inform Company of any matter in the Territory of which it is aware that is likely to affect, significantly,
the marketing of the Product; (iii) provide Company with market and sales information in a timely fashion including information
relating to the sales and marketing activities of Precision with respect to the Products; (v) inform Company of any reports of
irregularities, complaints or other adverse information received by Precision relating to the Product, its use or quality, and
not to take any action with regard thereto, unless required by law or the regulatory authorities in the Territory, without obtaining
Company’s prior written consent, such consent to be provided promptly and not unreasonably withheld by Company; (v) conduct
its marketing activities in a manner that reflects favorably at all times on the Product and the name, goodwill and reputation
of the Company; (vi) refrain from engaging in any illegal, deceptive, misleading or unethical practices, including but not limited
to, disparagement of the Company or the Product, and acceptance or payment of bribes, kickbacks or secret profits or any other
conduct that would violate applicable law; (vii) make no representations, warranties, guarantees or covenants, with respect to
the Product, other than those set forth in the Promotional Materials, as defined thereafter, provided to Precision by the Company;
and (viii) not modify any Promotional Materials without the Company’s prior written consent.

 

    	2

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

2.3Insurance
Obligations. Precision shall obtain and carry in full force and effect commercial general liability insurance, in reasonable
scope, which shall protect Company. Precision shall name Company as additional insured in said general liability insurance.

 

2.4Promotional
Materials. Company will furnish to Precision supplies of sales and technical information, literature and other marketing materials
regarding Company and the Product in order to aid Precision in effectively carrying out its activities under this Agreement. Company
hereby grants to Precision a nonexclusive license during the term of this Agreement to use and distribute such translations in
connection with the promotion of Products to Customers and Joint Customers. If Precision wishes to prepare its own marketing materials
regarding the Products, Company shall have the right, but not the obligation, to review any such advertising or promotional materials
prepared by Precision.

 

2.5Training.
Company will provide relevant training to Precision and its employees in such amounts as Company and Precision determines are reasonably
necessary to enable Precision to appropriately represent the Products to potential leads and Customers. Company will provide such
training at no additional charge to Precision; however, [***].

 

2.6Maximum Expenses.
Company’s total expenses [***], per contract year.

 

2.7Territory.
Precision will not solicit any Orders for Products from, or market or promote any Products to any prospective Customer that does
not have a principal place of business located within the Territory. If Precision receives any inquiry from a person or entity
outside the Territory, Precision will promptly communicate such inquiry to Company.

 

2.8Competing
Products.

 

(a)During
the Term, [***], Precision agrees that it will not market, promote, or solicit orders for any Competing Products from Customers
or Joint Customers in the Territory.

 

(b)During
the Term, [***], Precision agrees that it will not market, promote, or solicit orders for any Competing Products from Customers
or Joint Customers in the Territory.

 

    	3

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

2.9Records and
Inspection. Precision shall take commercially reasonable measures to retain originals or copies of all correspondence, quotations,
Orders and other documents relating to its obligations under this Agreement for a minimum of one (1) year following the termination
of this Agreement. Company and its designees shall have the right at any time during the term of this Agreement to examine such
books, records, correspondence, quotations, Orders and other documents relating to Precision’s obligations under this Agreement
as Company may deem necessary or appropriate upon reasonable advance notice to Precision. Company shall take commercially reasonable
measures to retain originals or copies of all correspondence, quotations, Orders and other documents relating to its obligations
under this Agreement for a minimum of one (1) year following the termination of this Agreement. Precision and its designees shall
have the right at any time during the term of this Agreement to examine such books, records, correspondence, quotations, Orders
and other documents relating to Company’s obligations under this Agreement as Precision may deem necessary or appropriate
upon reasonable advance notice to Company. Notwithstanding the above, in no case will Company be obligated to retain any documents
or copies thereof for a period exceeding five (5) years after the Term of this Agreement.

 

2.10[***].

 

	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]

[***].

 

[***].

 

[***].

 

[***].

 

2.11For
the removal of doubt, Company shall be entitled at any time during the term of this Agreement at its absolute discretion to cease
providing Products, in whole or in part, for reasons of medical safety, regulatory grounds, injunction (whether temporary or not),
or if Company no longer has the right to use any patent incorporated in Products.

 

3.Forecasts;
Sales

 

3.1Forecasts.
No less than thirty (30) days prior to each calendar quarter, Precision shall provide Company with a written [***] (each a “Forecast”).
Each Forecast is a non-binding estimate and shall not comprise a binding obligation on either party.

 

3.2Solicitation
of Potential Orders. Precision will be responsible for the sales process and for the solicitation of potential Orders from
a Customer or Joint Customer.

 

    	4

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

3.3Order Placement.
[***]. All sales to a Customer pursuant to such an Order may either be directly between Company and the Customer or via Precision.
All invoices in connection with Orders placed with Precision shall be rendered by Company. Company shall provide Precision with
a report within 10 days after the end of each month that will include the following: [***] for such Order. [***]. Reports shall
be delivered in electronic format and shall contain cumulative information from the Effective Date through the end of the then
current month. Company shall bear all credit and collection risk with respect to Orders accepted by Company.

 

3.4Post-Order
Customer Management. After a Customer places an Order with Company, Precision will provide liaison and customer management
support for Company with respect to the Customer, including (a) acting as a point of contact between the Customer and Company;
(b) regularly communicating with the Customer to identify any delays, problems, or issues that may arise in the course of fulfilling
the Order; (c) working diligently with Company to resolve any such issues; and (d) serving as a point of communication to the Customer
regarding delivery timetables and any required follow-up. Company will provide information and support to Precision in a timely
fashion and with commercially reasonable completeness, so as to enable Precision to satisfy this support role. Notwithstanding
the above, if the Customer is a Joint Customer, then Company shall act as liaison for customer management support.

 

3.5Sample Processing.Company
shall be solely responsible for all order processing and fulfillment related to Products. Company shall ensure that it operates
in accordance with applicable quality standards and in conformance with all necessary regulatory requirements. Company shall also
use commercially reasonable efforts to ensure expeditious turn-around times for fulfilling Orders for Products.

 

3.6Billing and
Payment. Company shall be solely responsible for invoicing Customers, or their insurance for accepted Orders, and Customers,
or their insurance will make payments directly to Company. If a Customer, or their insurance makes any payments to Precision for
Products, Precision will forward immediately any and all such payments and will instruct the Customer, or their insurance to make
future payments directly to Company.

  

4.Compensation.
During the term of this Agreement only, and subject to the terms and conditions of this Agreement, Company will pay Precision
the following compensation as consideration for services hereunder:

 

4.1Fees.
[***].

 

4.2Payment.
Unless otherwise specified, all amounts herein are stated and payable in U.S. Dollars. Fees shall be paid on a monthly basis within
the later of: [***]. Any amount that is not paid when due will accrue interest at the then-current prime rate quoted by Citibank
in New York City or the maximum rate allowable by applicable law, whichever is lower, from the due date until paid.

 

 

    	5

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

4.3Taxes. Precision
will be solely responsible for payment of all taxes, fees, duties, and other governmental charges, and any related penalties and
interest (collectively, “Taxes”) imposed on Precision as a result of any payments received by Precision from
Company under this Agreement.  Without derogating from the above, if Company is required to make
a payment to Precision subject to a deduction of tax or withholding tax, then (i) if such withholding or deduction obligation arises
as a result of any failure on the part of Company to comply with applicable laws or filing or record retention requirements, that
has the effect of modifying the tax treatment of the Parties hereto (a “Company Withholding Tax Action”), then the
sum payable by Company (in respect of which such deduction or withholding is required to be made) shall be increased to the extent
necessary to ensure that Precision receives a sum equal to the sum which it would have received had no such Company Withholding
Tax Action occurred, and (ii) otherwise, the sum payable by Company (in respect of which such deduction or withholding is required
to be made) shall be made to Precision after deduction of the amount required to be so deducted or withheld, which deducted or
withheld amount shall be remitted in accordance with applicable law.

 

4.4Audits.
During the Term, and for at least eighteen (18) months after the termination of this Agreement, each Party (the “Auditing
Party” ) will have the right, during normal business hours and upon at least ten (10) days prior notice, to have an independent
audit firm selected by the Auditing Party and reasonably acceptable to the other Party (the “Audited Party”
) to audit the Audited Party’s records relating to the Audited Party’s activities pursuant to this Agreement in order
to verify that the Audited Party has paid to the Auditing Party the correct amounts owed under this Agreement and otherwise complied
with the terms of this Agreement. The audit will be conducted at the Auditing Party’s expense, unless the audit reveals that
the Audited Party has underpaid the amounts owed to the Auditing Party by [***] or more during the audited period, in which case
the Audited Party will reimburse the Auditing Party for all reasonable costs and expenses incurred by the Auditing Party in connection
with such audit. The Audited Party will promptly pay to the Auditing Party any amounts shown by any such audit to be owing plus
interest as provided in Article 4.2. Such audits will be conducted no more than once in any period of six (6) consecutive months.
Any confidential or proprietary information of the Audited Party or its customers disclosed to the Auditing Party or the independent
accounting firm in the course of the audit will be subject to a confidentiality agreement reasonably acceptable to the Audited
Party to be signed by the Audited Party and such independent accounting firm.

 

 

 

5.Intellectual
Property

 

5.1Trademark
License. Subject to the terms and conditions of this Agreement, Company grants to Precision a non-transferable, non-exclusive,
revocable and limited license (without the right to sublicense) to use the Marks in the Territory on promotional materials solely
in connection with Precision’s marketing of Products as authorized herein. All use of the Marks pursuant to this Section
5.1 will inure to the benefit of Company. Except for the limited right to use the Marks as set forth in this Section 5.1,
nothing contained in this Agreement will be construed to grant Precision any right, title or interest in or to the Marks. Precision
acknowledges Company’s exclusive ownership of the Marks.

 

 

    	6

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

5.2Intellectual
Property Ownership. Precision acknowledges that Company and its licensors own and will retain all right, title and interest
in and to any and all worldwide intellectual property and proprietary rights embodied in the Products, including, but not limited
to, all copyrights, patent rights and trade secret rights, and in the Marks. Precision further acknowledges that it will have no
rights with respect to any of the foregoing other than the rights expressly set forth in this Agreement.

 

5.3Use of Marks.
Precision’s use of the Marks must comply with the Trademark Usage Guidelines as provided by Company to Precision and attached
as Exhibit G to this Agreement, as may be amended by Company from time to time upon sufficient prior written notice to Precision.

 

5.4Goodwill.
Precision shall ensure that all marketing materials or other documents on which the Marks are placed by Precision (the “Marked
Materials”) shall not reflect adversely upon the name, goodwill or reputation of Company or the Product. Precision agrees
that the Marked Materials shall be of such nature, style, appearance and quality as shall be adequate and suited to the protection
of the Marks and the goodwill associated therewith.

 

5.5Mark Combination.
Precision shall not use the Marks, or any part thereof, as part of or in combination with any other names or trademarks except
with Company’s prior written approval. Precision shall not use any confusingly similar or diluting mark, term or design,
and shall not attempt to register or aid any third party in using or attempting to register any such mark, term or design. Precision
shall not use any of the Marks in any manner that indicates that it is using such mark other than for the purpose of this Agreement.

 

5.6Samples of
Marked Materials. Precision shall submit to Company, free of cost, two samples of Marked Materials prior to the dissemination
or distribution of the Marked Materials. Company, at Company’s sole discretion, shall have the right to review the Marked
Materials submitted by Precision to confirm compliance with this Agreement. If Company disapproves of any sample of the Marked
Materials, Company shall provide Precision with the specific reasons for such disapproval. Precision shall promptly make all such
changes to the Marked Materials as Company shall request to protect the value of the Company Marks. If Precision refuses to submit
such samples, after being requested by Company to do so in writing or violates the provisions of this Section ‎5.6 and/or the
Company Trademark Usage Guidelines and does not submit the samples, or cure the violation within 30 days after being notified of
the same, Company shall have the right to revoke the Co Exclusive Appointment granted to Precision within 30 days of providing
written notice. The Company Marks and the goodwill associated therewith are and remain Company’s exclusive property.

 

 

    	7

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

6.Confidentiality

 

6.1Confidentiality.
Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the parties, each Party agrees that,
for the term of this Agreement and for [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose
to any third party and shall not use for any purpose other than as provided for in this Agreement all Confidential Information
furnished to it by the other Party pursuant to this Agreement, except that the foregoing obligations shall not apply to specific
information that the receiving Party can demonstrate by competent proof:

 

(a)was already
known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party;

 

(b)was generally
available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;

 

(c)became
generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of the Agreement;

 

(d)was disclosed
to the receiving party by a third party that was not under any obligations of confidentiality with respect thereto; or

 

(e)was independently
discovered or developed by the receiving Party without access to or use of Confidential Information of the disclosing Party.

 

Notwithstanding the foregoing, the receiving
Party shall be entitled to disclose Confidential Information pursuant to a requirement of a governmental agency or law, provided
that the receiving Party provides prompt written notice to the disclosing Party of such requirement or law so as to afford the
disclosing Party an opportunity to intervene and oppose or limit disclosure and/or obtain a protective order; provided, however,
without limiting any of the foregoing, it is understood that either Party may make disclosure of this Agreement and the terms hereof
in any filings required by the SEC (or any applicable stock exchange or regulatory organization), may file this Agreement as an
exhibit to any filing with the SEC (or any applicable stock exchange or regulatory organization) and may distribute any such filing
in the ordinary course of its business. However, to the maximum extent allowable by SEC (or any applicable stock exchange or regulatory
organization) rules and regulations, the Parties shall be obligated to maintain the confidentiality obligations set forth herein
and shall redact any confidential information set forth in such filings as may be reasonably requested by the disclosing Party.

 

6.2Publicity;
Disclosure of this Agreement.

 

(a)Except
as otherwise provided herein, neither party will use the name or logo of the other party in any marketing or promotional collateral,
websites, or other materials without the prior approval of the other party. Except as permitted in clause (b) below, each party
will obtain the other party’s written consent prior to any disclosure or any publication, presentation, public announcement,
or press release concerning the existence or terms and conditions of this Agreement

 

    	8

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

(b)Neither
party may disclose the terms and conditions of this Agreement to any third party (other than its attorneys, accountants, and other
professional advisors under a duty of confidentiality) without the prior consent of the other party except (a) as may be required
by law, a court order, or a governmental agency with jurisdiction, provided that, if possible, before making such a disclosure
the party making the disclosure first notifies the other party to give the other party an opportunity to limit such disclosure
or seek a protective order, and (b) to potential investors, lenders, purchasers of the party’s business, merger parties,
and underwriters in connection with their due diligence in future financings, loan transactions, acquisitions, mergers, or public
offerings, provided that such persons or entities agree in writing to keep the terms and conditions of this Agreement confidential.

 

6.3Press Release.
Upon execution of this Agreement, the Parties shall release a joint press release that shall be reviewed and approved in advance
by each Party. During the term of this Agreement, all material publicity, press releases and public announcements concerning material
information involving both Parties shall be reviewed in advance by each Party and shall be subject to written approval which will
not be unreasonably withheld. Company shall not require approval or review from Precision if conducting presentations and or business
and commercial communications in the regular course of business that make factual statements about Precision, as pertaining to
this Agreement. Company may use the Precision logo in its power point presentations whilst mentioning factual statements about
the Agreement.

 

6.4Injunctive
Relief. The Parties acknowledge that a breach or threatened breach of this Section 6 by either of the Parties may cause the
non-breaching Party to suffer irreparable harm and injury such that no remedy at law will adequately compensate the other Party.
Thus, the non-breaching Party shall have the right to obtain injunctive relief with respect to such breach or threatened breach.

 

 

 

7.Term
and Termination

 

7.1Term.

 

This Agreement will
commence on the Effective Date and will continue for a period [***];

 

7.2Termination

 

(a)Termination
for Cause. Upon the occurrence of a material breach or default as to any obligation hereunder by either Party and the failure
of the breaching Party to cure such material breach or default [***] after receiving written notice thereof from the non-breaching
Party, this Agreement may be terminated by the non-breaching Party by giving written notice of termination to the breaching Party,
such termination being immediately effective upon the giving of such notice of termination.

 

    	9

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

(b)Termination
by Company. Company shall have the right, but not the obligation, to terminate this Agreement:

 

(i)[***].

 

(ii)Immediately
upon notice, If Precision admits to being or is declared insolvent, or voluntary or involuntary proceedings are instituted by or
against it in bankruptcy, or receivership, or for a winding-up or for the dissolution or re-organization of its assets, which proceedings
are not dismissed within thirty (30) days thereafter.

 

(iii)Immediately
upon notice, based on medical safety, regulatory reasons, injunction (whether temporary or not), or if Company no longer has the
right to use any patent incorporated in Products.

 

(iv)[***].

 

(c)Termination
by Precision. Precision shall have the right, but not the obligation, to terminate this Agreement:

 

(i)Immediately
upon notice, If Company admits to being or is declared insolvent, or voluntary or involuntary proceedings are instituted by or
against it in bankruptcy, or receivership, or for a winding-up or for the dissolution or re-organization of its assets, which proceedings
are not dismissed within thirty (30) days thereafter.

 

(ii)Immediately
upon notice, based on medical safety, regulatory reasons, injunction (whether temporary or not), or if Company no longer has the
right to use any patent incorporated in Products.

 

7.3 Effect
of Termination; Survival

 

(a)Effect of Termination.
Upon termination or expiration of this Agreement for any reason, (a) Precision’s appointment as Company’s sales
representative in the Territory will immediately terminate, and Precision must immediately discontinue all use of the Company Marks
and remove all references to Company or the Products from Precision’s advertising and promotional materials; (b) each party
will return to the other party all Confidential Information of the other party and copies thereof and any other proprietary information
of the other party and certify in writing that it has fully complied with this requirement; and (c) [***].

 

(b)Survival. Section
1 (Definitions), Section 2.8 (Records and Inspection), 4.1 (Fees) ([***]), Section 5.2 (IP Ownership), Section 6 (Confidentiality),
Section 7.3 (Effect of Termination; Survival), Section 8 (Indemnity), Section 10.3 (Disclaimer), Section 11 (Limitation of Liability),
and Section 12 (Miscellaneous) will survive any termination or expiration of this Agreement. [***].

 

 

    	10

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

8.Indemnity.

 

8.1Indemnification
by Company. Company shall indemnify, defend and hold harmless Precision and its directors, officers, employees and agents from
and against any and all costs, expenses, damages, judgments and liabilities including reasonable attorneys’ fees incurred
by or rendered against Precision arising from any claim made or suit brought by a third party arising out of a breach by Company
of its representations, warranties or obligations under this Agreement or Company’s gross negligence or willful misconduct.
Precision shall give Company prompt written notice of any such claim or suit, and shall permit Company to undertake the defense
thereof, at Company’s expense. Precision shall cooperate in such defense to the extent reasonably request by Company, at
Company’s expense. In any claim made or suit brought for which Precision seeks indemnification under this Section 8.1, Precision
shall not settle, offer to settle or admit liability or damages without the prior written consent of Company.

 

8.2Indemnification
by Precision. Precision shall indemnify, defend and hold harmless Company and its directors, officers, employees and agents
from and against any and all costs, expenses, damages, judgments and liabilities including reasonable attorneys’ fees incurred
by or rendered against Company arising from any claim made or suit brought by a third party arising out of a breach by Precision
of its representations, warranties or obligations under this Agreement, including representations regarding misleading statements
as set forth in Section 10.3, or Precision’s gross negligence or willful misconduct. Company shall give Precision prompt
written notice of any such claim or suit, and shall permit Precision to undertake the defense thereof, at Precision’s expense.
Company shall cooperate in such defense to the extent reasonably request by Precision, at Precision’s expense. In any claim
made or suit brought for which Company seeks indemnification under this Section 8.2, Company shall not settle, offer to settle
or admit liability or damages without the prior written consent of Precision.

 

8.3Indemnification
Conditions and Procedures. Each party’s agreement to indemnify, defend and hold harmless the other party is conditioned
on the indemnified Party: (i) providing written notice to the indemnifying party of any claim or demand for which is it seeking
indemnification hereunder promptly after the indemnified party has knowledge of such claim; (ii) permitting the indemnifying party
to assume full responsibility to investigate, prepare for and defend against any such claim or demand, except that the indemnified
party may cooperate in the defense at its expense using its own counsel; (iii) assisting the indemnifying party, at the indemnifying
party’s reasonable expense, in the investigation of, preparing for and defense of any such claim or demand; and (iv) not
compromising or settling such claim or demand without the indemnifying party’s written consent.

 

    	11

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

9.Standstill.
Precision agrees that [***]. The foregoing provisions of this Section 9 shall no longer apply: (a) if the Company announces
publicly that it is seeking purchasers for the Company; (b) upon the commencement by a third party of a tender or exchange offer
for more than fifty percent (50%) of voting power of the outstanding voting securities of the Company; or (c) if the Company publicly
announces a transaction, or an intention to effect any transaction, which would result in: (1) the sale by the Company or one or
more of its subsidiaries of assets representing fifty percent (50%) or more of the consolidated earning power or assets of the
Company; and (2) the common shareholders of the Company immediately prior to such transaction owning less than fifty-one percent
(51%) of the outstanding common stock of the acquiring entity or, in the case of a merger transaction, the surviving corporation
(or, if the surviving corporation is a subsidiary of a parent company, the parent company).

 

10.Representations
and Warranties

 

10.1No Conflicts.
Each party represents and warrants that (a) such party has full power and authority to enter into and perform this Agreement, (b)
the person signing this Agreement on such party’s behalf has been duly authorized and empowered to enter into this Agreement;
and (c) as of the Effective Date, such party is not engaged in any activities or subject to any obligations that conflict with
any obligations hereunder, including any obligations to sell Competing Products.

 

10.2No Warranties
to Customers. Precision will make no representations or warranties regarding the Products to Customers, and will inform any
Customers that any such warranties will be provided directly from Company.

 

10.3Misleading
Statements. Precision agrees and undertakes that it will not knowingly make any false or misleading statement, representation,
or warranty, oral or written, concerning the Products.

 

10.4DISCLAIMER.
EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED,
OR STATUTORY, REGARDING THE PRODUCTS OR THE SERVICES PROVIDED HEREUNDER, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT OF THIRD-PARTY RIGHTS.

 

11.Limitation
of Liability. EXCEPT WITH RESPECT TO A BREACH OF ARTICLE 6, TO
THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER PARTY WILL BE LIABLE FOR ANY LOSS OF USE, INTERRUPTION OF BUSINESS,
OR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES OF ANY KIND (INCLUDING, WITHOUT LIMITATION, LOST PROFITS
OR LOST DATA) REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, TORT, OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. FOR CLARITY, THIS ARTICLE 11 SHALL NOT APPLY TO DAMAGES AWARDED TO THIRD PARTIES THAT ARE THE
SUBJECT OF A PARTY’S INDEMNIFICATION OBLIGATIONS HEREUNDER.

 

    	12

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

12.Miscellaneous

 

12.1Relationship
of Parties. Each Party is an independent contractor with respect to the other Party and is not an employee or legal representative
of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf
of the other Party.

 

12.2Notices.
Any and all notices or other communications required or permitted by this Agreement or by law to be served on or given to either
party hereto by the other party will be in writing unless otherwise provided and will be deemed duly served and given when personally
delivered to either of the parties to whom it is directed, or in lieu of such personal service (a) on the same day of transmission
by confirmed facsimile, (b) seven (7) days after deposit in the mail, first class air mail postage prepaid, or (c) two (2) business
days after being sent by express courier, addressed to the respective addresses set forth on the signature page to this Agreement
or such updated addresses as the parties may indicate in writing from time to time. all notices shall be addressed to the representatives
of the parties set out below:

 

If to Company:

 

Attention: C.E.O.

Rosetta Genomics Inc.

3711 Market St. Suite
740, Philadelphia, PA, 19104, USA.

Tel: 215.382.9000

Fax: 215.382.0815

 

 

With a Copy to (which
shall not constitute notice):

 

General Counsel

Rosetta Genomics Ltd.

10 Plaut St., Rechovot,
76706, Israel

Tel: +972.73.222.0700

Fax: +972.73.222.0701

 

 

If to Precision:

 

Attention – C.F.O.

Precision Therapeutics,
Inc.

2516 Jane St.

Pittsburgh, PA 15203

Tel: 412.432.1500

Fax: 412.481.1597

 

    	13

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

12.3Assignment.
[***]. This Agreement will be binding upon and will inure to the benefit of the parties hereto and their respective representatives,
heirs, administrators, successors and permitted assigns except as otherwise provided herein.

 

12.4Force Majeure.
Neither party will be responsible or liable to the other party for nonperformance or delay in performance of any terms or conditions
of this Agreement due to acts of God, government-imposed embargos, wars, disruptions in telecommunications services or the Internet,
threats or acts of terrorism, energy crises, riots, strikes or other labor disputes, shortages of labor or materials or other causes
beyond the reasonable control of the non-performing or delayed party.

 

12.5No Waiver.
Any waiver (express or implied) by either party of any duty or breach of this Agreement will not constitute a waiver of any other
or subsequent duty or breach. No provision of the Agreement will be waived by any act, omission or knowledge of a party or its
agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer
of the waiving party.

 

12.6Compliance
with Laws. Precision will obey all applicable laws and regulations in the performance of its duties and tasks under this Agreement.
Precision agrees to obtain, at its own expense, all registrations, licenses and approvals from any authorities and agencies in
the Territory which may be needed in order for Precision to perform its obligations hereunder.

 

12.7Severability.
In the event any provision of this Agreement is held to be invalid or unenforceable, such provision will be changed and interpreted
to accomplish the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions
will continue in full force and effect.

 

12.8Governing
Law and Jurisdiction. This Agreement will for all purposes be governed by and interpreted in accordance with the laws of the
State of [***] without giving effect to any conflict of laws principles that require the application of the laws of a different
state. The parties expressly agree that the United Nations Convention on the International Sale of Goods will not apply to this
Agreement. Any dispute arising out of or relating to this Agreement may be commenced in a state or federal court in [***], and
each party irrevocably submits to the jurisdiction and venue of such courts.

 

12.9Dispute
Resolution. Each Party agrees to negotiate in good faith to resolve any dispute, claim or controversy arising out of or related
to this Agreement. In the event the Parties are unable to resolve the dispute within fifteen (15) days following the commencement
of negotiations, each Party shall escalate the dispute through the appropriate levels of management, up to and including the level
of Chief Executive Officers of Company and Precision, until the resolution of the issue is achieved or the respective executives
cannot agree to a resolution of the dispute. Unless otherwise agreed to by both Parties, in no event shall the escalation process
exceed thirty (30) days, such dispute shall be finally settled by arbitration administered in accordance with the then existing
JAMS Comprehensive Arbitration Rules and Procedures applicable at the time of the commencement of the arbitration, by one (1) arbitrator
appointed in accordance with said rules. The decision of the arbitrator shall be final and binding on both Parties hereto. The
place of arbitration shall be [***]. Nothing in this Agreement shall be deemed as preventing either Party from seeking injunctive
relief (or any other provisional remedy) from any court having jurisdiction over the Parties and the subject matter of the dispute
as necessary to protect either Party’s name, Confidential Information, or any other proprietary rights. Judgment upon the
award may be entered in any court having jurisdiction, or application may be made to such court for judicial acceptance of the
award and/or an order of enforcement as the case may be.

 

    	14

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

12.10Construction.
The headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation
of this Agreement. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party will not
be applied in the construction or interpretation of this Agreement. Unless otherwise provided, the term “including”
as used herein will mean “including without limitation.” This Agreement, and any amendment or waiver of the terms hereof,
may be signed in counterparts, each of which will constitute an original and all of which together will constitute one and the
same instrument. Any signature may be delivered by facsimile, which will have the effect of an original signature.

 

12.11Entire
Agreement. This document constitutes the entire agreement of Company and Precision with regard to the subject matter hereof
and supersedes all prior and contemporaneous negotiations, statements and agreements, whether written or oral. This Agreement may
be amended only by a written document executed by duly authorized representatives of Company and Precision.

 

[Remainder
of page intentionally left blank]

 

 

    	15

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

In
Witness Whereof, the parties hereto have executed this Agreement as of the date first written above.

 

	
        Rosetta Genomics,
        Inc.

         

        By: /s/ Kenneth A. Berlin          

         

        Name: Kenneth A. Berlin            

         

        Title: President and CEO           

         

        Date: 10-15-12                             

         

         
	
        Precision Therapeutics,
        Inc.

         

        By:  /s/ Damian
F. Rippole            

         

        Name: Damian F. Rippole             

         

        Title: CFO                                       

         

        Date: 10-12-12                                 :

         

         

	 	 

 

 

    	16

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

EXHIBIT
A

PRODUCTS

 

		·	Company’s miRview® mets2 laboratory
developed test

 

 

    	17

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

EXHIBIT
B

[***]

 

[***].

 

 

	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	 	 	 	 	[***]

 

    	18

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

EXHIBIT
C

 

Company
Marks

 

miRview®

miRview® mets

miRview® meso

miRview® squamous

miRview® lung

miRview® mets2

miRview® kidney

Harnessing the power of microRNA

Rosetta Genomics

Rosetta Genomics (Logo)

 

 

    	19

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

EXHIBIT
G

 

Rosetta
Genomics Trademark Usage Guidelines

 

These Trademark Usage Guidelines (the "Guidelines")
set forth the rules for using or referring to the trademarks and service owned by Rosetta Genomics or its affiliates ("Rosetta").
For the purposes of these Guidelines, "Rosetta Genomics Trademark(s)" shall include all registered or unregistered trademarks
and service marks (such as words, names, symbols, devices, slogans, or combination of these) owned by Rosetta Genomics, including
but not limited to the trademarks and service marks listed on the Rosetta Genomics Trademark List.

 

Rosetta Genomics considers its trademarks
and service marks to be among its most valuable intellectual property assets. As such, Rosetta Genomics intends to take all appropriate
measures to preserve the strength of and retain its exclusive rights to use its marks. Rosetta Genomics asks that you assist us
by following these Guidelines. If you have any questions about the Guidelines, please direct them to legal@RosettaGenomics.com.

 

1.Prohibited
Uses Of Rosetta Genomics Trademarks

 

Do Not Use Rosetta Genomics Trademarks
as the Name of Your Company, Products, or Services, or As A Domain Name. You may not use or register in any jurisdiction, whether
foreign or domestic, any Rosetta Genomics Trademark as all or part of your company, product, or service name in a manner that is
likely to create confusion as to Rosetta Genomics’ sponsorship, affiliation or endorsement of your company, product, or service,
or that may dilute the Rosetta Genomics Trademark. Similarly, you may not use or register in any jurisdiction, whether foreign
or domestic, a domain name that incorporates any Rosetta Genomics Trademark in bad faith or in a manner that is likely to create
confusion as to Rosetta Genomics’ sponsorship, affiliation or endorsement of your company, product, or service.

 

Do Not Use Rosetta Genomics Logos Without
Permission. You may not use any Rosetta Genomics logo unless you have an agreement with or express written consent from Rosetta
Genomics authorizing such use.

 

Do Not Use Rosetta Genomics Trademarks
In False Or Misleading Advertising. Advertising for Rosetta Genomics or its products or services offered under the Rosetta Genomics
Trademarks must not be false or misleading in any way and must not be in violation of any applicable law, municipal ordinance,
or administrative agency regulation of any country.

 

    	20

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

Do Not Use Rosetta Genomics Trademarks
In Objectionable Material. You may not use Rosetta Genomics Trademarks on or in connection with any defamatory, scandalous, pornographic,
or other objectionable materials of any sort.

 

Do Not Use Rosetta Genomics Trademarks
To Disparage Rosetta Genomics. You may not use Rosetta Genomics Trademarks to disparage Rosetta Genomics, its products or services,
or in a manner that, in Rosetta Genomics’ reasonable judgment, may diminish or otherwise damage the reputation of Rosetta
Genomics or the goodwill in the Rosetta Genomics Trademarks.

 

2.Permissible
Uses Of Rosetta Genomics Trademarks

 

Use Rosetta Genomics Trademarks To Refer
To Rosetta Genomics’ Products Or Services. With the exception of Rosetta Genomics logos (the use of which must be expressly
authorized by Rosetta Genomics), you generally may use Rosetta Genomics Trademarks to refer to Rosetta Genomics’ products
or services in advertising, promotional, and sales materials, assuming that you have the necessary authority to sell or promote
Rosetta Genomics’ products or services, e.g. authorized reseller, licensee, etc.

 

Use Rosetta Genomics Trademarks To Indicate
A Relationship To Rosetta Genomics Products. You may indicate the relationship of your products and services to Rosetta Genomics’
products or services by using an accurate referential phrase in connection with your product or service provided that: (a) the
Rosetta Genomics Trademark appears less prominent than the product or service name; (b) the Rosetta Genomics Trademark is not a
part of or incorporated in your product or service name; and (c) the referential phrase is accurate and complies with the requirements
set forth in any license agreement with Rosetta Genomics.

 

3.Rules
For Proper Usage Of Rosetta Genomics Trademarks

 

Proper usage of Rosetta Genomics Trademarks
is important for their continued protection. Proper usage aids consumers who depend upon Rosetta Genomics’ tests and services
and helps prevent Rosetta Genomics Trademarks from losing their distinctiveness and becoming generic. Licensees of Rosetta Genomics
Trademarks may have different rules of usage set forth in their license agreement, in which case Licensees should follow those
guidelines.

 

Set Rosetta Genomics Trademarks Apart From
Surrounding Text. When a Rosetta Genomics Trademark is used in a non-stylized form, such as in the body text of an advertisement,
it should be set apart and distinguished from the other words in the text. In order to do this, the Rosetta Genomics Trademark
may be rendered in boldface type, italics, capital letters, underscored, or set in quotation marks.

 

 

 

    	21

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

Examples:

 

	CORRECT	INCORRECT
	A variety of companies offer Rosetta Genomics’ tests.	A variety of companies offer Rosetta genomics’ tests.
	A variety of companies offer miRview® tests.	A variety of companies offer miRview tests.

 

 

Do Not Abbreviate Or Alter The Spelling
Of Rosetta Genomics Trademarks. You should not vary the appearance of Rosetta Genomics Trademarks by abbreviating them, incorporating
them into acronyms, changing their spelling or using improper capitalization. The Rosetta Genomics Trademark List provides the
proper spelling and capitalization for each trademark.

 

Examples:

 

	CORRECT	INCORRECT
	Rosetta Genomics	Rosetta genomics
	miRview®	Mirview

 

 

Use The Proper Trademark Symbol. A Rosetta
Genomics Trademark should appear with the proper trademark symbol, which can be found on the Rosetta Genomics Trademark List. In
written materials, the appropriate symbol must be used with the first or most prominent appearance of the Rosetta Genomics Trademark
in headlines and the first time the Rosetta Genomics Trademark appears in body text. This appropriate symbol also should be used
on each subsequent page if the topic is different or if the pages can be separated and distributed independently. If the materials,
product packaging, or web page includes a properly licensed Rosetta Genomics logo, which already includes the appropriate trademark
symbol, it is not necessary to include a trademark symbol after the word "Rosetta Genomics" in the text in that material,
product packaging, or web page.

 

    	22

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

Use The Proper Trademark Attribution Statement.
All marketing collateral, advertisements, product packaging, web pages, manuals, and studies that include Rosetta Genomics Trademarks
also must include the proper trademark attribution statement crediting ownership of the Rosetta Genomics Trademarks to Rosetta
Genomics, Ltd. typically; the attribution statement is displayed at the end of the material, in the footer of the document, or
on the back of the package. The correct trademark attribution statement is:

 

Rosetta Genomics, the Rosetta Genomics
Logo [if applicable] [and any other trademark found on the Rosetta Genomics Trademarks List that are referred to or displayed in
the document] [is/are] trademark[s] or registered trademark[s] of Rosetta Genomics, Ltd or its affiliates in the U.S. and other
countries. Other names may be trademarks of their respective owners.

 

Examples:

 

* In materials displaying a Rosetta Genomics
logo and referring to the miRview ® mets2 test, the correct trademark attribution statement is:

 

Rosetta Genomics, the Rosetta Genomics
Logo and miRview are trademarks or registered trademarks of Rosetta Genomics, Ltd., or its affiliates in the U.S. and other countries.
Other names may be trademarks of their respective owners.

 

4.Usage
Rules For Rosetta Genomics As A Trade Name

 

"Rosetta Genomics" functions
not only as a trademark mark and service mark identifying goods and services offered by Rosetta Genomics, Ltd. and Rosetta Genomics
Inc., but also as trade names or company names referring to Rosetta Genomics, Ltd. and Rosetta Genomics, Inc. Trade names are nouns
and, therefore, should not be followed by a generic descriptor and may be used in the possessive form. When used as a trade name,
"Rosetta Genomics" should not be followed by a trademark symbol. Within documents, the first reference to the trade or
company name should be "Rosetta Genomics, Ltd." or “Rosetta Genomics, Inc.” "Rosetta Genomics"
can be used for subsequent references.

 

5.Usage
Rules for Rosetta Genomics Logos

 

You may not use any Rosetta Genomics logo
unless you have an agreement with or express written consent from Rosetta Genomics authorizing such use. In the event that you
are authorized to use a Rosetta Genomics logo, the use must comply with these additional guidelines (or the usage guidelines set
forth in your license agreement, if those guidelines differ).

 

    	23

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

    	 

    

 

 

Use Only The Approved Master Artwork. The
Rosetta Genomics logos are single, standalone pieces of artwork. When reproducing the logos, use only the master artwork provided
by Rosetta Genomics. Do not alter or distort the appearance of the logo in anyway, for example, by adding your own design elements
or colors or changing the font. The logo must always look sharp, clean, and well produced.

 

Allow A Minimum Clear Space Around The
Rosetta Genomics Logo. Always allow for a minimum clear space around the Rosetta Genomics logo. Never violate the clear space with
any graphic elements, words, or charts.

 

Maintain Legibility. Never reproduce the
logo in a manner that causes the logo to become illegible or blurry, which may happen if the logo is reproduced too small.

 

Do Not Use Rosetta Genomics Logos As A
Decorative Device. Do not use any Rosetta Genomics logos for purely decorative purposes in any marketing collateral, packaging,
or web site without the express written permission of Rosetta Genomics.

 

Misuse of Rosetta Genomics Trademarks by
Others

 

If you learn of any uses of any trademarks
that are confusingly similar to the Rosetta Genomics Trademarks, please notify Rosetta Genomics by sending an e-mail to legal@RosettaGenomics.com.
Similarly, if you become aware of any use of a Rosetta Genomics Trademark that violates any of the rules described above, including
failure to identify Rosetta Genomics Trademarks as belonging to Rosetta Genomics, Ltd., please notify us at legal@RosettaGenomics.com.
If possible, please provide a copy of the article or other medium in which the trademark violation appeared.

 

 

 

 

    	24

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit 10.1

PROMISSORY NOTE

 

	$300,000.00	Austin, Texas	February 28, 2013

 

FOR VALUE RECEIVED,
Crossroads Systems, Inc., a Delaware corporation (the “Maker”), promises to pay to ACT Capital Partners, LP
(the “Payee”), at Radnor Corporate Center Two, 100 Matsonford Road, Suite 111, Radnor, Pennsylvania 19087, or
at such other place as Payee may from time to time designate, in lawful money of the United States of America, the principal sum
of Three Hundred Thousand and no/100 Dollars ($300,000.00), or such lesser or greater amount that may be outstanding pursuant to
the terms of this Promissory Note (this “Note”), together with interest on the unpaid principal balance hereof
from time to time outstanding, as set forth below.

 

1.            Payments;
Warrants; Conversion.

 

(a)          All
principal on this Note shall be due and payable on the earlier of: (i) subject to the conversion option set forth in Section
1(b) below, the date that Maker consummates a financing transaction that results in net proceeds to Maker of at least Three
Million and no/100 Dollars ($3,000,000.00) (the “Next Financing”), and (ii) April 15, 2013 (collectively,
the “Maturity Date”), unless accelerated pursuant to the terms hereof. In the event that any principal amounts
remain outstanding on this Note as of the Maturity Date then, on the next succeeding day, Maker shall issue to Payee warrants as
set forth herein (the “Note Warrants”). The Note Warrants shall (A) be exercisable for 1,000 shares of the common
stock of Maker for each $10,000 of principal amount that remains outstanding on this Note as of the Maturity Date, (B) have a term
of five (5) years from the date of issuance, and (C) have an exercise price per share equal to the weighted average closing price
per share for Maker’s common stock on the primary market where Maker’s common stock is listed or quoted as of the date
of issuance of each Note Warrant. On each succeeding thirtieth (30th) day anniversary after the date of the initial issuance of
any Note Warrants, Maker shall issue to Payee additional Note Warrants exercisable for 1,000 shares of the common stock of Maker
for each $10,000 of principal amount that remains outstanding on this Note as of such thirtieth (30th) day anniversary.

 

(b)          In
the event that there are any amounts that remain outstanding under this Note and the Next Financing is completed prior to the occurrence
of item (ii) from Section 1(a), then Payee may elect to convert some or all of the principal that is still outstanding under
this Note into the securities that are issued in the Next Financing. Payee shall exercise this right by giving written notice to
Maker of its election to convert amounts of principal under this Note on or prior to the date that is two (2) days subsequent to
the date that Payee receives written notice of the consummation of the Next Financing from Maker. Such notice shall state how much
of the outstanding principal under this Note that Payee is electing to convert. Such conversion shall be at a discount of fifteen
percent (15%) to the issue price that securities are issued in the Next Financing. The conversion of this Note shall be deemed
to have been effected as of the close of business on the date on which Payee has given written notice to Maker of its election
to convert. At such time as the conversion has been effected, the rights of Payee under this Note, to the extent of the conversion,
shall cease and the person in whose name this Note is held upon such conversion shall be deemed to have become the holder of record
of the appropriate kind and quantity of securities issued in the Next Financing. As soon as possible after a conversion has been
effected (but in any event within five (5) business days), Maker shall deliver to the converting Payee (i) a certificate or certificates
representing the appropriate kind and quantity of securities issued in the Next Financing by reason of such conversion and (ii)
payment in an amount equal to the sum of all interest and the amount of any principal not so converted under this Note, and the
converting Payee shall execute and deliver to Maker such documents, instruments and agreements as the other parties to the Next
Financing have executed and delivered.

 

    	 

    	 

    

 

2.            Interest
Charges. Interest on this Note shall be equal to Thirty Thousand and no/100 Dollars ($30,000). Such interest shall be payable
on the Maturity Date (unless accelerated pursuant to the terms hereof).

 

3.            Prepayments.
Maker shall have the right to prepay, in whole or in part, the principal of this Note without premium or penalty.

 

4.            Covenants.
Maker covenants and agrees that, as long as any obligations owed by Maker to Payee or any part thereof are outstanding, Maker will
perform and observe, or cause to be performed and observed, the following covenants:

 

(a)          Reporting
Requirements. Maker will furnish to Payee:

 

(i)          Notice
of Litigation. Promptly after the commencement thereof, notice of all material actions, suits, and proceedings before any governmental
authority or arbitrator affecting Maker or its assets;

 

(ii)         Notice
of Default. As soon as possible and in any event immediately upon Maker’s knowledge of the occurrence of any Event of
Default (as defined herein) (or any event that with notice or lapse of time or both would become an Event of Default), a written
notice setting forth the details of such Event of Default and the action that Maker has taken and proposes to take with respect
thereto; and

 

(iii)        Notice
of a Next Financing. Within one (1) day of the occurrence thereof, written notice of the consummation of the Next Financing.

 

(b)          Maintenance
of Existence; Conduct of Business. Maker will use its commercially reasonable efforts to preserve and maintain its legal existence
and all of its material leases, privileges, licenses, permits, franchises, qualifications, and rights that are necessary in the
ordinary conduct of its business.

 

(c)          Maintenance
of Properties. Maker will use its commercially reasonable efforts maintain, keep, and preserve all of its properties necessary
to the proper conduct of its business in good repair, working order, and condition (ordinary wear and tear excepted) and make all
necessary repairs, renewals, replacements, betterments, and improvements thereof.

 

(d)          Further
Assurances. Maker will execute and deliver such further documents, instruments and agreements, and take such further actions
as may be requested by Payee to carry out the provisions and purposes of this Note, to evidence the obligations, and to create,
preserve, maintain, and perfect the liens of Payee.

 

(e)          Commitments.
Maker shall not commit to do or undertake any action the actual taking of which would be a breach of the covenants set forth herein.

 

5.           Events
of Default and Remedies.

 

(a)          Upon
the occurrence of an Event of Default, Payee or other holder of this Note may proceed to protect and enforce its rights against
Maker pursuant to the terms of this Note and applicable law. Payee shall have the following rights and remedies:

 

    	2

    	 

    

 

(i)          Acceleration.
Payee may declare all outstanding principal of this Note immediately due and payable, and the same shall thereupon become immediately
due and payable, without notice, demand, presentment, notice of dishonor, notice of acceleration, notice of intent to accelerate,
protest, or other formalities of any kind, all of which are hereby expressly waived by Maker;

 

(ii)         Judgment.
Payee may reduce any claim to judgment;

 

(iii)        Other
Rights. Payee may exercise any and all rights and remedies afforded by the laws of the State of Texas or any other jurisdiction,
by equity, or otherwise;

provided, however, that upon
the occurrence of an Event of Default under Section 5(b)(iv), Section 5(b)(v) or Section 5(b)(vi)
below, the aforesaid amounts payable by Maker under this Note shall thereupon become immediately and automatically due and payable.

 

(b)          An
“Event of Default” shall occur if:

 

(i)          Maker
fails to pay when due, whether by demand or otherwise, any amounts due under this Note when due;

 

(ii)         Maker
breaches any of its representations, warranties or covenants contained in this Note and such breach continues uncured or unremedied
for a period of five (5) days after the receipt of written notice of such default from Payee;

 

(iii)        An
“Event of Default” has occurred under that certain Fourth Amended and Restated Loan and Security Agreement effective
as of December 27, 2012 between Silicon Valley Bank and Crossroads Systems (Texas), Inc. and Silicon Valley Bank has accelerated
the maturity of Maker’s obligations thereunder;

 

(iv)         Maker
shall (A) apply for or consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee, examiner,
liquidator or the like of himself or of all or any substantial part of his property, (B) make a general assignment for the benefit
of his creditors, (C) commence a voluntary case under the United States Bankruptcy Code (as now or hereafter in effect, the “Bankruptcy
Code”), (D) institute any proceeding or file a petition seeking to take advantage of any other law relating to bankruptcy,
insolvency, reorganization, liquidation, dissolution, winding-up, or composition or readjustment of debts, (E) fail to controvert
in a timely and appropriate manner, or acquiesce in writing to, any petition filed against him in an involuntary case under the
Bankruptcy Code, or (F) other action for the purpose of effecting any of the foregoing;

 

(v)          A
proceeding or case shall be commenced, without the application, approval, or consent of Maker in any court of competent jurisdiction,
seeking (A) the composition or readjustment of his debts, (B) the appointment of a receiver, custodian, trustee, examiner, liquidator
or the like of Maker or of all or any substantial part of his property, or (C) similar relief in respect of Maker under any law
relating to bankruptcy, insolvency, reorganization, winding-up, or composition or adjustment of debts, and such proceeding or case
shall continue undismissed, or an order, judgment or decree approving or ordering any of the foregoing shall be entered and continue
unstayed and in effect, for a period of sixty (60) or more days, or (D) an order for relief against Maker shall be entered in an
involuntary case under the Bankruptcy Code; or

 

(vi)         Maker
admits in writing its inability to, or becomes generally unable to, pay his debts as such debts become due.

 

    	3

    	 

    

 

6.            No
Waiver. No failure on the part of Payee to exercise and no delay in exercising, and no course of dealing with respect to,
any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right,
power, or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power, or privilege
or impair any other right, power, or privilege. The rights and remedies provided for hereunder are cumulative and not exclusive
of any rights and remedies provided by law. Enforcement by the holder of this Note for the payment hereof shall not constitute
an election by such holder of remedies so as to preclude the exercise of any other remedy available to such holder.

 

7.            Waiver.
Maker and all endorsers, sureties, and guarantors hereof hereby jointly and severally waive
all exemption rights under any applicable law, and also waive presentment for payment, demand, notice of nonpayment, valuation,
appraisement, protest, demand, dishonor, notice of protest, notice of intent to accelerate, notice of acceleration, and all other
notices, and without further notice hereby consent to all renewals, extensions, or partial payments either before or after maturity.

 

8.            Costs
of Collection. If this Note is placed in the hands of any attorney for collection, or is collected by suit or through bankruptcy
proceedings, Maker agrees to pay Payee’s reasonable attorneys’ fees and disbursements in addition to other amounts
due.

 

9.            Severability.
If any provisions of this Note are held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the
remaining provisions will not be affected, and in lieu of such unenforceable provision there shall be added automatically as part
of this Note a provision as similar in terms as may be valid and enforceable.

 

10.         Notices.
All notices, demands and other communications provided for or permitted hereunder shall be made in writing, and shall be addressed
to the parties at the addresses of each party given in writing to the other parties. All notices shall be given (a) by personal
delivery, or (b) by electronic communication, with a confirmation sent by registered or certified mail, return receipt requested,
or (c) by registered or certified mail, return receipt requested. All notices shall be deemed delivered (i) if by personal delivery,
on the date of delivery if delivered during normal business hours, and, if not delivered during normal business hours, on the next
business day following delivery, (ii) if by electronic communication, on the date of receipt of the electronic communication, and
(iii) if solely by mail, on the date of the deposit of the mailing in an official U.S. post office mail depository. A party may
change its address by notice to the other party.

 

11.         Continuing
Agreement; Successors and Assigns. This Note shall (a) remain in full force and effect until payment and performance
in full of all of the obligations of Maker to Payee hereunder, and (b) be binding on Maker and its successors and assigns,
and shall inure to the benefit of Payee and its successors, transferees, and assigns.

 

12.         Counterparts.
This Note may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together
shall be deemed to constitute one instrument. Delivery of an executed counterpart of a signature page to this Note by facsimile
or other electronic transmission (including email and .pdf format) shall be as effective as delivery of a manually executed counterpart
of this Note.

 

    	4

    	 

    

 

13.         Effect
of Headings; Construction. The descriptive headings in this Note have been inserted for convenience only and shall not
be deemed to limit or otherwise affect the construction of any provision thereof or hereof. The parties have participated jointly
in the negotiation and drafting of this Note with counsel sophisticated in investment transactions. In the event an ambiguity or
question of intent or interpretation arises, this Note and the agreements, documents and instruments executed and delivered in
connection herewith shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring
or disfavoring any party by virtue of the authorship of any provisions of this Note and the agreements, documents and instruments
executed and delivered in connection herewith.

 

14.         Use
of Terms. Whenever used in this Note, the singular number will include the plural, and the plural number will include the
singular, and pronouns in the masculine, feminine, or neuter gender will include each other gender.

 

15.         Survival.
The representations, warranties and covenants of the parties contained in this Note shall survive the execution and delivery of
this Note.

 

16.         Waiver.
Maker and each surety, guarantor, endorser, and other party ever liable for payment of any sums of money payable on this Note jointly
and severally waive notice, presentment, demand for payment, protest, notice of protest and non-payment or dishonor, notice of
acceleration, notice of intent to accelerate, notice of intent to demand, diligence in collecting, grace, and all other formalities
of any kind, and consent to all extensions without notice for any period or periods of time and partial payments, before or after
maturity, and any impairment of any collateral securing this Note, all without prejudice to the holder.

 

17.         Governing
Law. This Note shall be governed by and construed in accordance with the laws of the State of Texas and the applicable
laws of the United States of America. 

 

18.         Waiver
of Jury Trial; Punitive Damages. Maker and Payee each irrevocably waives its right to a trial by jury of any claim or cause
of action based upon or arising out of or related to this Note or the transactions contemplated hereby or thereby, in any action,
proceeding or other litigation of any kind brought by either against the other, whether with respect to contract claims, tort claims,
or otherwise. Maker and Payee each agrees that any such claim or cause of action shall be tried by a court without a jury. Without
limiting the foregoing, the parties further agree that its right to a trial by jury is waived as to any action, counterclaim or
other proceeding which seeks, in whole or in part, to challenge the validity or enforceability of this Note or any provision hereof.
This waiver shall apply to any subsequent amendments, renewals, supplements or modifications to this Note, whether or not specifically
set forth therein. Maker and Payee each irrevocably waives any right such party may have to claim or recover in any litigation
any and all special, consequential, exemplary, or punitive damages (regardless of how named).

 

19.         Entire
Agreement. This Note embodies the final, entire agreement of Maker and Payee with respect to the indebtedness evidenced
hereby and supersedes any and all prior commitments, agreements, representations and understandings, whether written or oral, relating
thereto and may not be contradicted or varied by evidence of prior, contemporaneous or subsequent oral agreements or discussions
of Maker and Payee. There are no oral agreements between Maker and Payee.

 

    	5

    	 

    

 

IN WITNESS WHEREOF,
the undersigned has executed this Note at Austin, Texas to be effective as of the date first written above.

 

	 	MAKER:
	 	 
	 	CROSSROADS SYSTEMS, INC.
	 	 
	 	By:	/s/Brian Bianchi
	 	Name:	Brian Bianchi
	 	Title:	COO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]